475 related articles for article (PubMed ID: 21246383)
21. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
Chiu YM; Lai MS; Chan KA
PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
[TBL] [Abstract][Full Text] [Related]
22. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
24. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
25. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
Tien YC; Yen HH; Chiu YM
Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
27. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.
Mori S
Mod Rheumatol; 2011 Dec; 21(6):621-7. PubMed ID: 21528424
[TBL] [Abstract][Full Text] [Related]
28. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.
Clarke WT; Amin SS; Papamichael K; Feuerstein JD; Cheifetz AS
Clin Immunol; 2018 Jun; 191():59-62. PubMed ID: 29601854
[TBL] [Abstract][Full Text] [Related]
29. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
30. A Hospital-Based Analysis in the Department of Clinical Chemistry for the Patients with HBV Reactivation after Anti-Cancer or Immunosuppressive Therapy.
Matsuzaki T; Ohkubo K; Yuki M; Kawashima H; Matsunaga A
Rinsho Byori; 2015 Mar; 63(3):297-304. PubMed ID: 26524851
[TBL] [Abstract][Full Text] [Related]
31. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.
Solay AH; Acar A; Eser F; Kuşcu F; Tütüncü EE; Kul G; Şentürk GÇ; Gürbüz Y
Turk J Gastroenterol; 2018 Sep; 29(5):561-565. PubMed ID: 30260778
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
33. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.
Urata Y; Uesato R; Tanaka D; Kowatari K; Nitobe T; Nakamura Y; Motomura S
Mod Rheumatol; 2011 Feb; 21(1):16-23. PubMed ID: 20668905
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
36. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
Yenilmez E; Cetinkaya RA
Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
[TBL] [Abstract][Full Text] [Related]
37. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
38. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
[TBL] [Abstract][Full Text] [Related]
39. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.
Patel A; Yapali S; Lok AS
Hepatol Int; 2016 Jan; 10(1):139-46. PubMed ID: 26272106
[TBL] [Abstract][Full Text] [Related]
40. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
